Author

William Wilcox

Institution: Emory University

Observed institution: Emory University

OpenAlex ID: A5110126429

Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms

2014 · Michael Whyte, Edward Leung, et al. · Bone Abstracts · 11

eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study

2022 · John Bernat, Myrl Holida, et al. · Genetics in Medicine · 7

SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia

2020 · Ravi Savarirayan, Louise Tofts, et al. · Journal of the Endocrine Society · 1

CO47 Clinical Expert Opinion on the Impact of Vosoritide on Health and Function in Children With Achondroplasia

2025 · Ravi Savarirayan, Carlos Bacino, et al. · Value in Health

Baseline Characteristics of Patients With Fabry Disease Enrolled in the Pegunigalsidase Alfa Expanded-Access Program

2022 · Ankit Mehta, William Wilcox, et al. · Journal of the American Society of Nephrology

OP021: Vosoritide for children with achondroplasia: Growth velocity and pubertal milestones

2022 · Melita Irving, Julie Hoover-Fong, et al. · Genetics in Medicine

Glucosylceramide Synthase Inhibition with Venglustat in Classic Fabry Disease Patients Leads to Progressive Reduction of Endothelial Cell Globotriaosylceramide Inclusion Volume

2020 · Behzad Najafian, William Wilcox, et al. · Journal of the American Society of Nephrology

Works count: 7

Citation count: 19

H-index: 2

I10-index: 1